Tag: MD

Scaling of MD with domain decomposition on JUWELS Cluster – Developers discussions

GROMACS version: 2024-dev-20240201-787d96c7a9-unknownGROMACS modification: YesI’m conducting some performance tests on the JUWELS Cluster, trying to see the improvement in performance that DD can bring within a single node. GROMACS build infoHere, GROMACS was built using GCC v11.4.0, uses OpenMP and OpenMPI v4.1.5, and builds its own FFTW v3.3.8. JUWELS Cluster…

Continue Reading Scaling of MD with domain decomposition on JUWELS Cluster – Developers discussions

Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

TOPLINE: Belantamab mafodotin plus a combination of bortezomib and dexamethasone improved median progression-free survival (PFS) by 23 months in patients with relapsed or refractory multiple myeloma compared with daratumumab alongside the same combination. METHODOLOGY: Belantamab mafodotin, a first-in-class anti-BCMA monoclonal antibody conjugate, was approved in the US in 2020 for…

Continue Reading Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

Assessing the Durability, Tolerability of Loncastuximab in R/R DLBCL

CASE A 73-year-old woman presented with fever, headaches, and 7-lb unintentional weight loss​. Medical history: no family history of cancer, and hyperlipidemia that was well controlled with simvastatin. Physical exam: palpable bilateral cervical lymphadenopathy​ Laboratory results: lactate dehydrogenase, 265 U/L (280 U/L upper limit); Hemoglobulin, 10.8 g/dL; bilirubin, 1.3 mg/dL…

Continue Reading Assessing the Durability, Tolerability of Loncastuximab in R/R DLBCL

The Henry M. Jackson Foundation for the Advancement of Military Medicine hiring Senior Bioinformatics Scientist in Bethesda, MD

Join the HJF Team!The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) is a nonprofit organization dedicated to advancing military medicine. We serve military, medical, academic and government clients by administering, managing and supporting preeminent scientific programs that benefit members of the armed forces and civilians alike….

Continue Reading The Henry M. Jackson Foundation for the Advancement of Military Medicine hiring Senior Bioinformatics Scientist in Bethesda, MD

Pacritinib Shows Transfusion Independence Benefits in Myelofibrosis

Bart Scott, MD Professor, Transplantation Program Clinical Research Division Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair Fred Hutchinson Cancer Center Seattle, WA Targeted Oncology: Could you summarize the approved Janus kinase (JAK) inhibitors for patients with myelofibrosis? BART SCOTT, MD: Ruxolitinib (Jakafi) was approved in 2011, fedratinib (Inrebic) in…

Continue Reading Pacritinib Shows Transfusion Independence Benefits in Myelofibrosis

Searching For Giant Exoplanets Around M-dwarf Stars (GEMS) I: Survey Motivation

Green triangles show an estimate of the heavyelement content (MZ ) of GEMS from planetary interior models (Thorngren et al. 2016) compared to the Class II disk dust mass (Md) estimates as orange squares (Manara et al. 2022) and the median (and 1-σ) trend seen in the Lupus sample (Ansdell…

Continue Reading Searching For Giant Exoplanets Around M-dwarf Stars (GEMS) I: Survey Motivation

Shedding Light on BIA-ALCL Risks

In a society that celebrates individuality and self-expression, the journey to aesthetics takes many forms. One such road, taken by countless women seeking empowerment and confidence, is breast augmentation. This blog dives deep into the dark and flip side of breast augmentation- Allergan breast implant lawsuits. Before answering the query…

Continue Reading Shedding Light on BIA-ALCL Risks

Umbrella Sampling using Cp2k

Dear all, I’m trying to carry out umbrella sampling for a dimeric system. My collective variable is center of mass to center of mass distance. The COLVAR and CONSTRAINT section is as follows. I’m getting different error with different modifications. Can anyone suggest me how to correct it ? Thanks…

Continue Reading Umbrella Sampling using Cp2k

Twisted DNA Increases CRISPR Off-target Effects

At the end of 2023, the FDA approved Casgevy for sickle cell disease, its first approval for a therapeutic that used the genome editing tool clustered regulatory interspaced palindromic repeats (CRISPR) to specifically inactivate a human gene as a treatment for a genetic disease. While CRISPR-based gene therapies could potentially…

Continue Reading Twisted DNA Increases CRISPR Off-target Effects

Investigation of the Flipping Dynamics of 1, N6-Ethenoadenine in Alkyladenine DNA Glycosylase

dataset posted on 2024-02-09, 02:43 authored by Bin Liu, Yanping Qi, Xiaowei Wang, Xin Gao, Yuan Yao, Lu Zhang Alkyladenine DNA glycosylase (AAG) is an essential enzyme responsible for maintaining genome integrity by repairing several DNA lesions damaged by alkylation or deamination. Understanding how it can recognize and excise the…

Continue Reading Investigation of the Flipping Dynamics of 1, N6-Ethenoadenine in Alkyladenine DNA Glycosylase

ADC Therapeutics (ADCT) Rises 43% in a Month: Here’s Why

ADC Therapeutics ADCT is a commercial-stage biotech company focused on developing novel antibody-drug conjugates (ADC) to treat patients with hematologic malignancies and solid tumors. Currently, ADC Therapeutics has only one marketed drug in its portfolio, Zynlonta, which the FDA approves to treat relapsed or refractory (r/r) diffuse large B-cell lymphoma…

Continue Reading ADC Therapeutics (ADCT) Rises 43% in a Month: Here’s Why

Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC

Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC Compared with lenvatinib (Lenvima) plus placebo, adding pembrolizumab (Keytruda) to lenvatinib resulted in consistent overall (OS) and progression-free survival (PFS) outcomes previously found in the phase 3 LEAP-002 trial (NCT03713593) of patients with advanced hepatocellular carcinoma (HCC). However, 35% of…

Continue Reading Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC

Debian — Details of package cp2k in bookworm

Ab Initio Molecular Dynamics CP2K is a program to perform simulations of solid state, liquid, molecular and biological systems. It is especially aimed at massively parallel and linear scaling electronic structure methods and state-of-the-art ab-initio molecular dynamics (AIMD) simulations. CP2K is optimized for the mixed Gaussian and Plane-Waves (GPW) method…

Continue Reading Debian — Details of package cp2k in bookworm

First patients treated with Abbott’s pulsed field ablation offering

Abbott announced this week that more than 30 patients in Australia were treated with the company’s new pulsed field ablation (PFA) system, representing the first time the technology has been used to treat arrhythmias such as atrial fibrillation in a clinical setting. The procedures were performed by Prash Sanders, MBBS,…

Continue Reading First patients treated with Abbott’s pulsed field ablation offering

Breaking a ligand with umbrella sampling – User discussions

ryanm January 19, 2024, 6:40pm 1 GROMACS version: 2022GROMACS modification: YesHere post your questionCan GROMACS umbrella sampling break two bonded atoms in a ligand? Example: using umbrella sampling to show the maximum force to break the carbon and oxygen bond in carbon dioxide molecule. Bonds cannot break or form in…

Continue Reading Breaking a ligand with umbrella sampling – User discussions

Ravgen wins $57M in patent infringement suit against Natera

A jury in Austin, TX, awarded biotech firm Ravgen $57 million in damages in its patent infringement lawsuit against Natera. The jury agreed that Natera’s Panorama prenatal screening test infringes on the Columbia, MD-based Ravgen’s patent rights in cell-free DNA (cfDNA) technology, according to a Ravgen statement. Ravgen’s lawsuit, which…

Continue Reading Ravgen wins $57M in patent infringement suit against Natera

Chinese Scientists Shared Coronavirus Data with US Before Pandemic

In late December 2019, eight pages of genetic code were sent to computers at the National Institutes of Health in Bethesda, Md. Unbeknown to American officials at the time, the genetic map that had landed on their doorstep contained critical clues about the virus that would soon touch off a…

Continue Reading Chinese Scientists Shared Coronavirus Data with US Before Pandemic

Genomic insights into Plasmodium vivax population structure and diversity in central Africa | Malaria Journal

Hamblin MT, Di Rienzo A. Detection of the signature of natural selection in humans: evidence from the Duffy blood group locus. Am J Hum Genet. 2000;66:1669–79. Article  CAS  PubMed  PubMed Central  Google Scholar  Hamblin MT, Thompson EE, Di Rienzo A. Complex signatures of natural selection at the Duffy blood group…

Continue Reading Genomic insights into Plasmodium vivax population structure and diversity in central Africa | Malaria Journal

N6-methyladenosine modification positively regulate Japanese encephalitis virus replication | Virology Journal

Burgess HM, Depledge DP, Thompson L, Srinivas KP, Grande RC, Vink EI, Abebe JS, Blackaby WP, Hendrick A, Albertella MR, Kouzarides T, Stapleford KA, Wilson AC, Mohr I. Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication. Genes Dev. 2021;35:1005–19. Article  CAS  PubMed  PubMed Central  Google Scholar  Chambers…

Continue Reading N6-methyladenosine modification positively regulate Japanese encephalitis virus replication | Virology Journal

FDA grants full approval to erdafitinib for FGFR3-positive urothelial carcinoma

The FDA has granted a full approval to erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least 1 line of prior systemic therapy. It is not recommended for patients who,…

Continue Reading FDA grants full approval to erdafitinib for FGFR3-positive urothelial carcinoma

GPU support and installation – User discussions

tebg January 19, 2024, 8:51am 1 GROMACS version: 2023.3GROMACS modification: Yes (I think??) I’ve just started setting up a new PC with the main goal of running MD simulations, and I’m trying to test out a simple membrane simulation generated by CHARMM-GUI. I installed GROMACS with GPU support, but I…

Continue Reading GPU support and installation – User discussions

Doctoral Researchers in Molecular Medicine and Life Sciences job with UNIVERSITY OF HELSINKI

As part of the Nordic EMBL Partnership for Molecular Medicine, the Institute for Molecular Medicine Finland (FIMM) invites applications for the positions of Doctoral Researchers in Molecular Medicine and Life Sciences We currently have 2-4 openings for doctoral researchers as part of the FIMM-EMBL international PhD programme starting in August 2024. In this interdisciplinary…

Continue Reading Doctoral Researchers in Molecular Medicine and Life Sciences job with UNIVERSITY OF HELSINKI

Comparison of capture-based mtDNA sequencing performance between MGI and illumina sequencing platforms in various sample types | BMC Genomics

Hu T, Chitnis N, Monos D, Dinh A. Next-generation sequencing technologies: an overview. Hum Immunol. 2021;82(11):801–11. Article  CAS  Google Scholar  Jeon SA, Park JL, Park SJ, Kim JH, Goh SH, Han JY, Kim SY. Comparison between MGI and Illumina sequencing platforms for whole genome sequencing. Genes Genomics. 2021;43(7):713–24. Article  CAS …

Continue Reading Comparison of capture-based mtDNA sequencing performance between MGI and illumina sequencing platforms in various sample types | BMC Genomics

Gromacs: gmx::test::anonymous_namespace{observablesreducer.cpp}::Subscriber Class Reference

This browser is not able to show SVG: try Firefox, Chrome, Safari, or Opera instead. [legend] Helper class that models an MD module that needs to make a subscription to ObservablesReducer. static constexpr int  s_subscriberBufferMinimumSize = 3   Ensure that each subscriber sends an interesting amount of data.   static…

Continue Reading Gromacs: gmx::test::anonymous_namespace{observablesreducer.cpp}::Subscriber Class Reference

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

In a recent conversation with CancerNetwork®, Sara A. Hurvitz, MD, FACP, senior vice president and director of the Clinical Research Division at Fred Hutch Cancer Center and head of the Division of Hematology and Oncology at the University of Washington Department of Medicine, discussed new treatment options for patients with…

Continue Reading HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

Gmxmmpbsa energy part – User discussions

GROMACS version:2022.3GROMACS modification: Yes/NoHere post your questionPreProcessorError: Could not find gromos54a7_atb.ff/forcefield.itpI have runned my md and obtained all the files now on dealing with the binding energy part using gmxmmpbsa I am experiencing error such that gromos54a7_atb.ff/forcefield.itp could not find. I have included this in the topol file and my…

Continue Reading Gmxmmpbsa energy part – User discussions

Error during production MDrun – User discussions

SP06 January 1, 2024, 6:11am 1 GROMACS version:2021.4GROMACS modification: Yes/NoHere post your question I am simulating my protein in cyclohexane solvent. On the final production MD run, i got the following error-Fatal error:The X-size of the box (5.875432) times the triclinic skew factor (1.000000) issmaller than the number of DD…

Continue Reading Error during production MDrun – User discussions

Study sheds more light into benefits of immunotherapy

According to the Brigham researchers’ next-generation sequencing, changing existing cancer care standards might allow around 6,000 more patients in the United States to benefit from immunotherapy treatment each year. Immunotherapy is a highly successful treatment for cancer patients with mismatch repair failure, and new research finds additional cancer patients…

Continue Reading Study sheds more light into benefits of immunotherapy

Cost and Benefit: Lisocabtagene Maraleucel is Cost Effective as Second-line Treatment for Lymphoma

Lisocabtagene maraleucel (liso-cel; Breyanzi®; Bristol-Myers Squibb), a CD19-directed genetically modified autologous T-cell immunotherapy, also known as chimeric antigen receptor (CAR) T-cell therapy, is a cost effective second line treatment for relapsed and refractory diffuse large B-cell lymphoma (r/r DLBCL). This conclusion is based on results from a study published in…

Continue Reading Cost and Benefit: Lisocabtagene Maraleucel is Cost Effective as Second-line Treatment for Lymphoma

Form 1 ClinVar RCV survey

Download: pdf | pdf ClinVar RCV Page Survey 2022 Start of Block: Default Question Block OMB Approval Info OMB Control Number: 0925-0648 Expiration Date: 06/30/2024 Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data…

Continue Reading Form 1 ClinVar RCV survey

New Geriatric Assessment Tools in DLBCL

Suchitra Sundaram, MD, reflects on a prospective study presented at ASH 2023 that investigated the use of geriatric assessment tools to better gauge which patients with non-Hodgkin lymphoma will experience treatment toxicities. In exploring the use of geriatric assessment tools to predict treatment toxicities, Dr Sundaram highlights the significance of…

Continue Reading New Geriatric Assessment Tools in DLBCL

Generate topology file for glucose – User discussions

horlust December 29, 2023, 10:15am 1 GROMACS version: 2021.4-2GROMACS modification: No Hello everyone! I am fairly new to GROMACS. I’ve been able to successfully run simulations for some small molecules with the OPLS-AA force field. My problem has always been the generation of the topology files. Using pdb2gmx seems impossible…

Continue Reading Generate topology file for glucose – User discussions

Research Associate – Bioinformatics, Cancer Proteomics & Personalized Medicine Job in Vancouver for UBC

Academic Job Category Faculty Non Bargaining Job Title Research Associate – Bioinformatics, Cancer Proteomics & Personalized Medicine Department Lange Laboratory | Department of Pathology and Laboratory Medicine | Faculty of Medicine (Philipp Lange) Posting End Date January 31, 2024 Note: Applications will be accepted until 11:59 PM on the day…

Continue Reading Research Associate – Bioinformatics, Cancer Proteomics & Personalized Medicine Job in Vancouver for UBC

Neutrophil extracellular trap-induced intermediate monocytes trigger macrophage activation syndrome in adult-onset Still’s disease | BMC Medicine

Wang MY, Jia JC, Yang CD, Hu QY. Pathogenesis, disease course, and prognosis of adult-onset Still’s disease: an update and review. Chin Med J (Engl). 2019;132(23):2856–64. Article  CAS  PubMed  Google Scholar  Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603–18. Article …

Continue Reading Neutrophil extracellular trap-induced intermediate monocytes trigger macrophage activation syndrome in adult-onset Still’s disease | BMC Medicine

Bioinformatics Full Time jobs in Colorado | $50,000

Broaden your search Bioinformatics, Full Time, $50,000 – $74,999, Colorado 1 Life Sciences, Full Time, $50,000 – $74,999, Postdoc, Colorado 1 Bioinformatics, Full Time, $50,000 – $74,999, Postdoc, United States 5 Refine your search Sign up for job alerts …

Continue Reading Bioinformatics Full Time jobs in Colorado | $50,000

SC-282 Shows Promising Results for DLBCL

The molecule SC-2882, developed by Scenic Biotech, has shown promising preclinical results for treating diffuse large B cell lymphoma (DLBCL), according to a recently published press release. Although R-CHOP chemotherapy is an effective treatment for most patients with DLBCL, a significant percentage of patients are resistant to treatment or relapse…

Continue Reading SC-282 Shows Promising Results for DLBCL

Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Key Points Question  What is the association of PIK3CA mutations, response to therapy, and outcome by hormone receptor (HR) status and intrinsic subtype among patients with ERBB2/HER2-positive early breast cancer (EBC) treated in a clinical trial? Findings  In this cohort study of 184 patients enrolled in the phase 3 trial…

Continue Reading Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Achievements, accolades highlight past year at VUMC | VUMC Reporter

  Editor’s note — the following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2023.   Whole-genome sequencing agreement Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies,…

Continue Reading Achievements, accolades highlight past year at VUMC | VUMC Reporter

How MRD Testing Can Help

MRD testing is incredibly valuable in informing clinical decision-making in the treatment of lymphoid malignancies, and its adoption by all oncologists is crucial in the era of precision medicine. During my 10 plus years of practicing medicine, I have seen the blood cancer treatment landscape transform, as the development of…

Continue Reading How MRD Testing Can Help

Research spotlight: Structural analysis and i

Martin Taylor, MD, PhD, a physician investigator in the Department of Pathology at Massachusetts General Hospital and an instructor in Pathology at Harvard Medical School, is the lead corresponding author of a new study in Nature, Structural Analysis and Inhibition of Human LINE-1 ORF2 Protein Reveals Novel Adaptations and Functions….

Continue Reading Research spotlight: Structural analysis and i

Sacramento bee obituaries for today

Sacramento,CA Obituaries. The Dignity Memorial® online obituary search tool gives you access to obituaries from thousands of locations across North America. You can search by first or last name, state and publication date. Once you find the obituary you are looking for, you can get important information about upcoming services,…

Continue Reading Sacramento bee obituaries for today

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes | Antibodies

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes Details Category: Antibodies Published on Tuesday, 19 December 2023 09:37 Hits: 742 TROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoadjuvant treatment for early-stage triple negative and HR…

Continue Reading Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes | Antibodies

LncRNA/circRNA-mRNA networks in CARAS | JIR

Introduction Combined allergic rhinitis and asthma syndrome (CARAS), a new terminology introduced by the World Allergy Organization (WAO) in 2004, is an allergic reaction that occurs in the respiratory tract, including upper respiratory tract allergy (allergic rhinitis, AR) and lower respiratory tract allergy (asthma, AS).1,2 The incidence of AS in…

Continue Reading LncRNA/circRNA-mRNA networks in CARAS | JIR

Diving into PyTorch: A Beginner’s Tale of Contribution | by Weinheimergracia | Dec, 2023

Hey there, fellow code wranglers and AI enthusiasts! I’m Cami, your friendly neighborhood tech explorer, and I’m about to take you on a wild ride through my latest adventure: contributing to PyTorch without being an expert in it. Yes, you read that right! My Unexpected Journey into PyTorch So, I…

Continue Reading Diving into PyTorch: A Beginner’s Tale of Contribution | by Weinheimergracia | Dec, 2023

Novel Combination Therapy Impresses With Safety/Efficacy in DLBCL

Christopher J. Melani, MD, assistant research physician in the Lymphoid Malignancies Branch at the Center for Cancer Research, National Cancer Institute, discusses updated data from the phase 1b/2 ViPOR trial (NCT03223610) of the combination of venetoclax (Venclexta), ibrutinib (Imbruvica), prednisone, obinutuzumab (Gazyva), and lenalidomide (Revlimid), in patients with diffuse large…

Continue Reading Novel Combination Therapy Impresses With Safety/Efficacy in DLBCL

FDA to Review Omalizumab for Patients With Food Allergies

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for omalizumab for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to 1 or more foods in adults and pediatric patients aged 1 year and older with food allergy….

Continue Reading FDA to Review Omalizumab for Patients With Food Allergies

UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Faculty and trainees from the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) joined the world’s largest hematology community to discuss the latest updates in blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held December 9-12, 2023 in San Diego and online. At the meeting,…

Continue Reading UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Running GROMACS with OpenCL on accelerator – User discussions

Aastha December 19, 2023, 11:23am 1 GROMACS version:2023.3GROMACS modification: YesHere post your questionI am trying to run GROMACS on an accelerator connected to PCI bus.I made the following modifications to the code: changed CL_DEVICE_TYPE_GPU to CL_DEVICE_TYPE_ALL Added my accelerator vendorcheckGpu returns value TRUE, so the dummy kernel is able to…

Continue Reading Running GROMACS with OpenCL on accelerator – User discussions

Where Is the ‘Microbiome Revolution’ Headed Next?

Human microbiome research has progressed in leaps and bounds over the past decades, from pivotal studies begun in the 1970s to the launch of the Human Microbiome Project in 2007. Breakthroughs have laid the groundwork for more recent clinical applications, such as fecal microbiota transplantation (FMT), and advanced techniques to…

Continue Reading Where Is the ‘Microbiome Revolution’ Headed Next?

The Next Chapter in Genome Editing? Tome Emerges from Stealth with $213M

Rahul Kakkar, MD, Tome Biosciences president and CEO While the CRISPR community celebrates the recent first FDA approval of a CRISPR-Cas9 therapy (Casgevy), new entities are making strides in their efforts to write perhaps the definitive new chapter in programmable genome editing. Last week, Tome Biosciences—a developer of genome editing…

Continue Reading The Next Chapter in Genome Editing? Tome Emerges from Stealth with $213M

ASH 2023: Lymphoma Studies May Inform Practice

Studies presented at the ASH Annual Meeting 2023 provided new insights and updates that may inform the treatment of lymphomas. Results from the phase 3 SYMPATICO trial showed that adding venetoclax to ibrutinib can improve progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL).1 These results…

Continue Reading ASH 2023: Lymphoma Studies May Inform Practice

Casgevy, sickle cell gene-editing therapy, favored for EU approval

A European Medicines Agency committee has issued a positive opinion on the gene-editing therapy Casgevy (exagamglogene autotemcel) in treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The Committee for Medicinal Products for Human Use (CHMP) recommendation will be considered by the European Commission in making a final approval decision…

Continue Reading Casgevy, sickle cell gene-editing therapy, favored for EU approval

A super-pangenome of the North American wild grape species | Genome Biology

Alston JM, Sambucci O. Grapes in the world economy. In: Cantu D, Walker MA, editors. The grape genome. Springer International Publishing; 2019. p. 1–24. Google Scholar  Rahemi A, Dodson Peterson JC, Lund KT. Grape rootstocks and related species. Cham: Springer International Publishing; 2022. Walker MA, Heinitz C, Riaz S, Uretsky…

Continue Reading A super-pangenome of the North American wild grape species | Genome Biology

molecular dynamics – How do we calculate diffusion coefficient when GROMACS MSD graph with two slopes?

I calculated the MSD using the gmx msd -f run05.part0005.xtc -s run05.tpr -o msd_200-250ns.xvg. As a result, I got a graph with 2 slopes as attached. In the MD simulation, I followed a simulated annealing schedule for every 25 ns. Since I get the kink at 25 ns, I believe…

Continue Reading molecular dynamics – How do we calculate diffusion coefficient when GROMACS MSD graph with two slopes?

Lipid vesicle(CHARMM Gui files) simulation in GROMACS – User discussions

GROMACS version: 2022.1 and 2020GROMACS modification: Yes/NoHere post your questionHello, I am trying to simulate Lipid based vesicle in GROMACS on Frontera super-computer. The following command I am using to run the simulation. But I am getting error messages. Since I am new I don’t understand the error message perfectly….

Continue Reading Lipid vesicle(CHARMM Gui files) simulation in GROMACS – User discussions

Tome Biosciences CEO Rahul Kakkar on recent funding round

Tome Biosciences made a splash last week when it emerged from stealth mode with $213 million in funding. The programmable genomic integration (PGI) company based in Watertown, Massachusetts, raised significant financing from investors like Andreessen Horowitz (a16z) Bio + Health, Arch Venture Partners, Fujifilm Corporation and others.  Tome CEO Rahul Kakkar, MD…

Continue Reading Tome Biosciences CEO Rahul Kakkar on recent funding round

Darzalex Faspro combo of help with multiple myeloma diagnosis, transplant

Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to significantly better outcomes for people who are newly diagnosed with multiple myeloma and transplant eligible. That’s according to four-year data from the Phase 3 PERSEUS (NCT03710603) clinical…

Continue Reading Darzalex Faspro combo of help with multiple myeloma diagnosis, transplant

Improving the diagnosis of infection: a prosp

Scientists from Necker-Enfants Malades Hospital (AP-HP), the Institut Pasteur, Université Paris Cité, Inserm, Université Paris-Est Créteil and the Alfort National Veterinary School, coordinated by Professor Marc Eloit and Dr. Anne Jamet in collaboration with Dr. Jacques Fourgeaud and Beatrice Regnault, studied the role of global genetic characterization of samples (or…

Continue Reading Improving the diagnosis of infection: a prosp

Genetic Mechanisms Driving Predisposition to Childhood Kidney Cancer Uncovered

Wilms tumor, also known as nephroblastoma, is a rare kidney cancer that mainly affects children. The average age of diagnosis of Wilms tumor in children depends upon whether one or both kidneys are affected. If one kidney is affected, unilateral Wilms tumor, the age at diagnosis usually is 42–47 months….

Continue Reading Genetic Mechanisms Driving Predisposition to Childhood Kidney Cancer Uncovered

Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma

Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP). Combination chemotherapy involving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) — and before that, CHOP alone —…

Continue Reading Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma

Pembrolizumab/Chemo Receives European Approval in First-Line GI Cancers

The approval was based on data from both the phase 3 KEYNOTE-859 study (NCT03675737) and the phase 3 KEYNOTE-966 study (NCT04003636). The European Commission has granted approval to pembrolizumab (Keytruda) and chemotherapy in 2 gastrointestinal cancer indications, according to a press release from Merck.1 In particular, pembrolizumab is available in…

Continue Reading Pembrolizumab/Chemo Receives European Approval in First-Line GI Cancers

Programmable Genomic Integration Company Raises Over $200 Million

Tome Biosciences – a programmable genomic integration company – recently announced it has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI). PGI enables the insertion of any DNA sequence of any size into any programmed genomic location. And the company has raised…

Continue Reading Programmable Genomic Integration Company Raises Over $200 Million

BMS Ends Phase 3 Trial of Nivolumab and Relatlimab in CRC

Colorectal Cancer: © peterschreiber.media – stock.adobe.com Bristol Myers Squibb is ending the phase 3 RELATIVITY-123 trial (NCT05328908) investigating nivolumab (Opdivo) and relatlimab (Opdualag) in patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer (CRC) with disease progression following 1, but no more than 4 lines of therapy, due to…

Continue Reading BMS Ends Phase 3 Trial of Nivolumab and Relatlimab in CRC

FDA Fails to Address DNA Adulteration Concerns

The following article originally appeared on Dr. Robert Malone’s Substack, and is reprinted here verbatim with permission. Robert Malone, MD, MS; Malone Institute December 15, 2023, 2:30 PM EST (Madison VA and Tallahassee FL) The failure of government regulatory authorities to identify and disclose DNA fragment contamination of…

Continue Reading FDA Fails to Address DNA Adulteration Concerns

2 global itepekimab Phase 3 trials for COPD open new US sites

Two international Phase 3 clinical trials testing the investigational antibody itepekimab in people with chronic obstructive pulmonary disease (COPD) are continuing to enroll patients — specifically, former smokers — at hundreds of centers worldwide, with several new sites recently opened in the U.S. All of the new sites are being…

Continue Reading 2 global itepekimab Phase 3 trials for COPD open new US sites

Exploring How Poxviruses Dismantle Antiviral Responses

Derek Walsh, PhD, professor of Microbiology-Immunology, was senior author of the study published in Nature Communications. Northwestern Medicine investigators led by Derek Walsh, PhD, professor of Microbiology-Immunology, have discovered how poxviruses disarm and evade mitochondrial-driven antiviral responses for their replication in host cells, according to findings published in Nature Communications….

Continue Reading Exploring How Poxviruses Dismantle Antiviral Responses

Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care

Systemic therapy and surgery have become mainstays in the treatment of patients with endometrial cancer, although further research is necessary to delineate the optimal use of radiation and later-line immunotherapy in this patient population, according to Hope Cottrill, MD. The phase 3 NRG-GY018 trial (NCT03914612) evaluated the efficacy and safety…

Continue Reading Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care

Metagenomic Sequencing Market Set to Reach $7.1 Billion With a 17.6% CAGR by 2033

The Metagenomic Sequencing Market witnessed a significant global revenue of US$ 1.2 Billion in 2022. It is projected to experience a remarkable growth rate of 17.6% from 2023 to 2033, ultimately reaching a valuation of US$ 7.1 Billion by the conclusion of the forecast period. The Metagenomic Sequencing Market has emerged…

Continue Reading Metagenomic Sequencing Market Set to Reach $7.1 Billion With a 17.6% CAGR by 2033

Nicox screens first patient in Whistler Phase 3b trial of NCX 470 in glaucoma

NCX 470, a novel NO-donating bimatoprost eye drop, is currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.(Image courtesy of Adobe Stock) Nicox SA announced the first patient has been screened in the Whistler Phase 3b clinical trial investigating the…

Continue Reading Nicox screens first patient in Whistler Phase 3b trial of NCX 470 in glaucoma

Nidhi Sahni receives TAMEST Mary Beth Maddox Award for research in molecular pathways of cancer progression

Newswise — HOUSTON ― Nidhi Sahni, Ph.D., associate professor of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center, has been awarded the 2024 Mary Beth Maddox Award and Lectureship in cancer research from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST). Sahni is being honored for her…

Continue Reading Nidhi Sahni receives TAMEST Mary Beth Maddox Award for research in molecular pathways of cancer progression

Unraveling predisposition in bilateral Wilms tumor

A ‘mosaic’ of predisposing factors  Wilms tumor is the most common kidney cancer of childhood, but just 5-7% of all Wilms tumor patients are diagnosed with bilateral Wilms tumor. Patients with bilateral Wilms tumor are diagnosed younger and often have precursor lesions called nephrogenic rests (clusters of undifferentiated embryonic kidney…

Continue Reading Unraveling predisposition in bilateral Wilms tumor

Unilever Bioinformatics Jobs – BTech Biotech Apply Online

“Unilever is Hiring: Research Executive Job in Bengaluru – Apply Now!” –Must See– Unilever Bioinformatics Jobs – BTech Biotech Apply Online Research Executive Job at Unilever Job ID: R-79328 Category: Research/Development Location: Bengaluru, Karnataka Date posted: 12/13/2023 About Unilever: Be part of the world’s most successful, purpose-led business. Work with…

Continue Reading Unilever Bioinformatics Jobs – BTech Biotech Apply Online

Stanford Researchers Harness Deep Learning with GLOW and IVES to Transform Molecular Docking and Ligand Binding Pose Prediction

Deep learning has the potential to enhance molecular docking by improving scoring functions. Current sampling protocols often need prior information to generate accurate ligand binding poses, limiting scoring function accuracy. Two new protocols, GLOW and IVES, developed by researchers from Stanford University, address this challenge, demonstrating enhanced pose sampling efficacy….

Continue Reading Stanford Researchers Harness Deep Learning with GLOW and IVES to Transform Molecular Docking and Ligand Binding Pose Prediction

Advanced Pose Sampling Methods GLOW and IVES Improve Deep Learning in Molecular Docking

Deep learning has the potential to revolutionize molecular docking by improving the accuracy of scoring functions. However, current sampling protocols often require prior information, limiting the effectiveness of these scoring functions. In a breakthrough study, researchers from Stanford University have developed two new protocols, GLOW and IVES, that address these…

Continue Reading Advanced Pose Sampling Methods GLOW and IVES Improve Deep Learning in Molecular Docking

Tackle manufacturer Hardy & Greys looks to trim HQ staff

From Hardy & Greys – Tackle manufacturer looks to trim HQ staff One of the UK’s leading fishing tackle manufacturers is planning to restructure its HQ organization to reduce costs and increase profitability. Hardy & Greys is a major employer in the market town of Alnwick in Northumberland and has…

Continue Reading Tackle manufacturer Hardy & Greys looks to trim HQ staff

Challenges In The Management Of Cutaneous Lymphoma

New York, USA. Symptoms of early-stage cutaneous lymphoma often mimic those of non-malignant cutaneous malignancies such as psoriasis or atopic dermatitis, leading to misdiagnosis and missed opportunities for appropriate treatment.(1) While most patients with cutaneous lymphoma do not progress to advanced-stage, life-threatening disease, for the subgroup of patients who do,…

Continue Reading Challenges In The Management Of Cutaneous Lymphoma

FDA Fails to Address DNA Adulteration Concerns, Resorting To Gaslighting Instead

Thanks, Jan! Lets get this amplified! Go Joe Ladapo! t.co/kgaIolmKnR — Robert W Malone, MD (@RWMaloneMD) December 16, 2023 Someone said: “If reports I’ve read in the news are correct, that many high level members of the FDA are heavily invested in the covid vaccines, then it make sense that…

Continue Reading FDA Fails to Address DNA Adulteration Concerns, Resorting To Gaslighting Instead

Accepted samtools 1.19-1 (source) into unstable

—–BEGIN PGP SIGNED MESSAGE—– Hash: SHA512 Format: 1.8 Date: Fri, 15 Dec 2023 16:17:11 +0100 Source: samtools Architecture: source Version: 1.19-1 Distribution: unstable Urgency: medium Maintainer: Debian Med Packaging Team <debian-med-packag…@lists.alioth.debian.org> Changed-By: Étienne Mollier <emoll…@debian.org> Changes: samtools (1.19-1) unstable; urgency=medium . * [73082b5] New upstream version 1.19 * [b86781d] d/rules:…

Continue Reading Accepted samtools 1.19-1 (source) into unstable

Edesa Biotech Reports Fiscal Year 2023 Results

TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2023 and provided an update on its business. During the year, Edesa reported favorable…

Continue Reading Edesa Biotech Reports Fiscal Year 2023 Results

What Makes Lymphoma Turn Lethal?

A study by researchers at Columbia and the Hong Kong University of Science and Technology is helping to clarify how low-grade lymphoma changes as it develops into a more aggressive tumor, which could lead to the development of new treatments. Though often incurable, many low-grade B-cell lymphomas are slow to…

Continue Reading What Makes Lymphoma Turn Lethal?

The initial estimative of -nt parameter – User discussions

GROMACS version: 2022.6GROMACS modification: NoHi, community.I would like to know, how gromacs calculate an initial estimate for number of threads used on mdrun? For example, when run this command “gmx mdrun -deffnm md_0_1 -nb gpu” , for system 1, i can see all my 24 threads been using. Nonetheless, when…

Continue Reading The initial estimative of -nt parameter – User discussions

Undefined reference to mbedTLS functions – Nordic Q&A – Nordic DevZone

Hi all!  So I’m trying to use mbedTLS methods in my project. I got it to work on SDK v1.9.0 but when upgrading to v.2.4.0 I get  a lot of “undefined references” to methods regarding mbedTLS.I see that there is some other issues regarding this but those haven’t solved my…

Continue Reading Undefined reference to mbedTLS functions – Nordic Q&A – Nordic DevZone

Adbry Approval Expanded to Pediatric Patients with Atopic Dermatitis

The Food and Drug Administration (FDA) has expanded the approval of Adbry® (tralokinumab-ldrm) to include pediatric patients aged 12 to 17 years with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Previously, the interleukin-13 antagonist…

Continue Reading Adbry Approval Expanded to Pediatric Patients with Atopic Dermatitis

Sickle Cell Disease Gene Therapies Approved by FDA Highlighting Potential of CRISPR/Cas9 Technologies

In a landmark decision last week, the US Food and Drug Administration (FDA) approved two treatments involving cell-based gene therapies.  An agency within the US Department of Health and Human Services, the FDA assures the safety, effectiveness, and security of human and veterinary drugs, vaccines, and other biological products for…

Continue Reading Sickle Cell Disease Gene Therapies Approved by FDA Highlighting Potential of CRISPR/Cas9 Technologies

FDA Approves Implant for Glaucoma

The US Food and Drug Administration (FDA) has approved an intracameral implant with 75 mcg of travoprost to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).  The iDose TR (Glaukos Corp) is inserted into a corneal incision on the temple side of the eye….

Continue Reading FDA Approves Implant for Glaucoma

Researchers discover first-ever link between hemoglobin-like protein and normal heart development

cygb2 mutant phenotype presents organ laterality defects. a CRISPR/Cas9 mediated genome editing of cygb2. Two different gRNA were targeted to exon 1 (denoted by red text) and resulted in 4 bp and 1 bp frame shift mutations (beginning in the blue shaded region of the predicted protein structure) named cygb2801a and cygb2801b,…

Continue Reading Researchers discover first-ever link between hemoglobin-like protein and normal heart development

Identification of Differentially Expressed Genes in Human Colorectal Cancer Using RNASeq Data Validated on the Molecular Level with Real-Time PCR

Allam RM, Al-Abd AM, Khedr A, Sharaf OA, Nofal SM, Khalifa AE, Mosli HA, Abdel-Naim AB (2018) Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells. Toxicol Lett 291:77–85 Article  CAS  PubMed  Google Scholar  Andrews S et al (2010) FastQC: a quality control tool…

Continue Reading Identification of Differentially Expressed Genes in Human Colorectal Cancer Using RNASeq Data Validated on the Molecular Level with Real-Time PCR

Key Insights on Advances in DLBCL

Suchitra Sundaram, MD, breaks down the wealth of data presented at ASH 2023 and provides initial impressions of several key study results centering on new and encouraging treatments for diffuse large B-cell lymphoma. Starting with a landmark analysis of a phase 2 trial testing the efficacy of the bispecific antibody…

Continue Reading Key Insights on Advances in DLBCL

Unlocking the human genome: Innovative machin

image:  LoGoFunc identifies harmful (left) and harmless (right) genetic variations in the Vasopressin V2 receptor protein using a structure predicted by AlphaFold2. This helps explain how genetic changes affect proteins. view more  Credit: Stein et al., Genome Medicine New York, NY [December 14, 2023]—In a novel study, researchers from the…

Continue Reading Unlocking the human genome: Innovative machin

Karuna Therapeutics Inc. (KRTX) Reports Publication of Phase 3 EMERGENT-2 Trial Data on KarXT

Karuna Therapeutics, Inc. (NASDAQ: KRTX) today announced that results from the Phase 3 EMERGENT-2 trial of KarXT (xanomeline-trospium) in adults with schizophrenia were published in The Lancet. The manuscript shares KarXT data showcasing a clinically meaningful and statistically significant reduction in positive and negative symptoms of schizophrenia among adult patients…

Continue Reading Karuna Therapeutics Inc. (KRTX) Reports Publication of Phase 3 EMERGENT-2 Trial Data on KarXT

Computational Biology, Bioinformatics Internship – Summer 2024 at Takeda Pharmaceutical

By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’sPrivacy Noticeand Terms of Use. I further attest that all information I submit in my employment application is true…

Continue Reading Computational Biology, Bioinformatics Internship – Summer 2024 at Takeda Pharmaceutical

FDA Approves First Pulsed Field Ablation System for AF

The US Food and Drug Administration (FDA) has approved the PulseSelect Pulsed Field Ablation (PFA) System (Medtronic) for the treatment of both paroxysmal and persistent atrial fibrillation (AF), the manufacturer has announced. The technology uses microsecond-scale pulsed electrical fields for pulmonary vein isolation (PVI) to reduce AF and is the…

Continue Reading FDA Approves First Pulsed Field Ablation System for AF

Tome Biosciences Raises $213M to Commercialize MIT Developed Genome Editing Tech

Methods of editing the genome are powering the development of new cell and gene therapies for diseases that have been challenging to treat. Companies like Tome Biosciences are part of a wave of startups building commercial platforms that leverage CRISPR/Cas9 and other genome editing technologies.  Earlier this week, Tome raised…

Continue Reading Tome Biosciences Raises $213M to Commercialize MIT Developed Genome Editing Tech

MD Anderson Research Highlights for December

HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at…

Continue Reading MD Anderson Research Highlights for December

Approval of gene therapy ‘transformative’ in SCD

New regulatory decisions in the U.S. and the U.K. have made Casgevy (exagamglogene autotemcel) the first gene-editing therapy to be approved for adults and adolescents with sickle cell disease (SCD) who experience painful vaso-occlusive crises (VOCs). With these recent approvals, the therapy from Vertex Pharmaceuticals and CRISPR Therapeutics also became…

Continue Reading Approval of gene therapy ‘transformative’ in SCD

Archaic Introgression Shaped Human Circadian Traits | Genome Biology and Evolution

Abstract When the ancestors of modern Eurasians migrated out of Africa and interbred with Eurasian archaic hominins, namely, Neanderthals and Denisovans, DNA of archaic ancestry integrated into the genomes of anatomically modern humans. This process potentially accelerated adaptation to Eurasian environmental factors, including reduced ultraviolet radiation and increased variation in…

Continue Reading Archaic Introgression Shaped Human Circadian Traits | Genome Biology and Evolution

A high-resolution transcriptomic and spatial atlas of cell types in the whole mouse brain

Mouse breeding and husbandry All experimental procedures related to the use of mice were approved by the Institutional Animal Care and Use Committee of the AIBS, in accordance with NIH guidelines. Mice were housed in a room with temperature (21–22 °C) and humidity (40–51%) control within the vivarium of the AIBS…

Continue Reading A high-resolution transcriptomic and spatial atlas of cell types in the whole mouse brain

CP2K QMMM Calculation seems to randomly crash

Dear all, I have encountered a very disturbing phenomena.  My system is fairly simple: One Na+ in water (up to 800 water molecules). I generated the system using tleap. The plan is the following: Since full semi empirical MD with XTB is costly for 801 atoms, I tried to calculate…

Continue Reading CP2K QMMM Calculation seems to randomly crash

[llvm-bugs] [Bug 75428] clang crash when build IPEX code.

Issue 75428 Summary clang crash when build IPEX code. Labels clang Assignees Reporter xuhancn The error msg: “`cmd Stack dump: 0. Program arguments: /usr/bin/clang++ -DAT_PARALLEL_OPENMP=1 -DUSE_C10D_GLOO -DUSE_DISTRIBUTED -DUSE_RPC -DUSE_TENSORPIPE -Dintel_ext_pt_cpu_EXPORTS -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/csrc/include -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/csrc/cpu -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/csrc/cpu/aten -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/csrc/cpu/utils -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/csrc/cpu/jit -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/csrc/jit -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/csrc/utils -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/third_party/ideep/mkl-dnn/include -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/csrc/cpu/tpp -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/third_party/libxsmm/include -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/build/Release/csrc/cpu/csrc/cpu/cpu_third_party/ideep/mkl-dnn/include -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/third_party/ideep/include -I/home/xu/anaconda3/envs/ipex_cpu/include/python3.12 -I/home/xu/anaconda3/envs/ipex_cpu/include -I/home/xu/anaconda3/envs/ipex_cpu/lib/python3.12/site-packages/torch/include/torch/csrc/api/include -I/home/xu/conda_spaces/ipex_cpu/frameworks.ai.pytorch.ipex-cpu/third_party/ideep/mkl-dnn/src/../include -isystem /home/xu/anaconda3/envs/ipex_cpu/lib/python3.12/site-packages/torch/include -fPIC…

Continue Reading [llvm-bugs] [Bug 75428] clang crash when build IPEX code.

Error in MD simulation – User discussions

GROMACS version:2021.7GROMACS modification: NoHere post your questionHello everyone,I’m trying to perform a MD simulation on a protein-ligand complex in acetonitrile as solvent at 45C but it seems there is something wrong with my system since this error pops up.Can anyone please help?**” WARNING: Listed nonbonded interaction between particles 887 and…

Continue Reading Error in MD simulation – User discussions